Mainz Biomed
Mainz Biomed Stock Spikes on Positive Data for mRNA-Enhanced Colorectal Cancer Screening Assay
In top-line data, Mainz Biomed's enhanced ColoAlert detected CRC with 94 percent sensitivity and 97 percent specificity, and advanced adenoma with 81 percent sensitivity.
Mainz Biomed Partners With German Diagnostic Laboratory to Offer ColoAlert Test
The collaboration with Ärztliches Labor Dr. Buhlmann will provide Mainz Biomed with greater access to Germany's private health insurance segment.
In Brief This Week: Illumina, Thermo Fisher, Tempus, Bionano Genomics, Danaher, More
News items for the week of Aug. 14, 2023